Merck’s potential $3B EyeBio acquisition puts drugmaker back in ophthalmology market
Today the company announced a deal worth $3 billion to buy EyeBio and its first-in-class trispecific antibody Restoret, marking the pharma’s return to the ophthalmology space after nearly a decade.